Drug Discovery World

NOVEMBER 30, 2023

This presentation covered three primary drivers for a protein expression model: speed, cost and sustainability. “It The next presentation attended in this track was the keynote presentation, which was given by Kate Smith, PhD, Head of UK Protein & Cell Sciences at GSK.

Protein Expression 147

Protein Expression Engineering DNA Therapies 147

Drug Discovery World

FEBRUARY 28, 2023

As we turn our focus to new potential applications and disease areas for the platform, scientists and companies must consider the potential life-saving impact on rare, inherited diseases, says Archana Gupta , PhD, staff scientist in genetic sciences at Thermo Fisher Scientific. The mRNA transcripts are then purified from the IVT reaction.

Disease 130

Disease Treatment Vaccine DNA 130

Codon

DECEMBER 10, 2023

Natural science can learn a great deal from physics, where progress is made by proposing new models and then demonstrating their veracity through experiments. Such a model would make it possible to discover protein functions by scraping metagenomic databases , or to create proteins with functions that exist nowhere in nature.

Protein Expression 71

Protein Expression DNA Laboratories Engineering 71

Drug Discovery World

APRIL 30, 2024

This is essential to its use as a therapeutic agent and gives the technology a vast versatility making it suitable to treating a wide range of diseases – especially those that have high protein expression. mRNA-based approaches can produce proteins / peptides by using protein synthesis which is processed in a transfected cell 1.

Therapies 130

Therapies RNA Vaccine Small Molecule 130

Drug Discovery World

NOVEMBER 9, 2023

Peter O’Callaghan, PhD, Head of Expression System Sciences, Biologics and Licensing, Lonza, on: ‘Solve bispecific heavy-light chain mispairing with bYlok technology’. Klaus Wagenbauer, PhD, Founder & CEO, Plectonic, on: ‘Programmable DNA-origami-based T cell engagers: PTE’.

Engineering 130

Engineering Therapies Protein Production Science 130

Drug Discovery World

NOVEMBER 13, 2023

Enkelejda Miho, PhD, Professor, University of Applied Sciences and Arts Northwestern Switzerland, and Managing Director, aiNET, on: ‘The singular immune response to dengue and machine learning identification of antibodies in high-throughput sequences’.

Engineering 147

Engineering Science Bioinformatics Vaccine 147

Drug Target Review

SEPTEMBER 10, 2024

The current landscape of protein drug development is characterised by accelerated timelines where new drugs are approved in months rather than years. For example, advances in media and feeds have contributed to higher cell protein expression by optimising nutrient availability and reducing accumulation of waste products within a culture.

Clinical Supply 64

Clinical Supply Drug Development Production Animal Testing 64

Alta Sciences

APRIL 17, 2024

Five Promising Treatment Areas in Early-Phase Drug Development in 2024 aasimakopoulos Wed, 04/17/2024 - 15:52 Early-phase drug development is an ever-changing landscape, as emerging science leads to new promising areas of research for the treatment of human health issues.

Drug Development 52

Drug Development Treatment FDA Approval Drugs 52

Codon

APRIL 9, 2023

“Computer science is to biology what calculus is to physics.” ” This technology could be used to design protein therapeutics that can bind to, and “shut down,” harmful or misfolded proteins in living cells. Read *De novo design of modular peptide-binding proteins by superhelical matching.

Therapies 52

Therapies RNA Engineering Vaccine 52

Drug Target Review

MAY 4, 2023

The researchers turned to CRISPR —a gene editing tool that uses “molecular scissors to cut DNA ,” according to Sanjana—to edit the regions identified by GWAS. The researchers then use CRISPR to target each of the regions of the genomes implicated by GWAS and conduct single-cell sequencing to evaluate gene and protein expression.

Disease 52

Disease Small Molecule Protein Expression Research 52